CAS 151038-96-9: DOXO-EMCH

Descrizione: DOXO-EMCH, con il numero CAS 151038-96-9, è un composto chimico che funge da profarmaco della doxorubicina, un noto agente chemioterapico. Questo composto è caratterizzato dalla sua capacità di rilasciare selettivamente doxorubicina nei tessuti mirati, migliorando l'efficacia terapeutica del farmaco e minimizzando la tossicità sistemica. DOXO-EMCH è tipicamente progettato per migliorare la farmacocinetica e la biodistribuzione della doxorubicina, consentendo un trattamento del cancro più efficace. La struttura di DOXO-EMCH include un collegamento che facilita il rilascio di doxorubicina dopo la scissione enzimatica, che è spesso mediata da enzimi specifici presenti nel microambiente tumorale. Questo approccio mirato mira ad aumentare la concentrazione del farmaco attivo nel sito tumorale, migliorando così il risultato complessivo del trattamento. Inoltre, la solubilità, stabilità e profilo metabolico del composto sono cruciali per le sue prestazioni in contesti clinici. Con il proseguire della ricerca, DOXO-EMCH rappresenta una promettente opportunità nello sviluppo di terapie contro il cancro più efficaci con effetti collaterali ridotti.

Formula: C₃₇H₄₂N₄O₁₃

InChI: InChI=1S/C37H42N4O13/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8,10-11,17,20,22,27,32,42,46,48,50-51H,3-5,9,12-16,38H2,1-2H3,(H,40,43)/t17-,20-,22-,27-,32+,37-/m0/s1

InChI key: InChIKey=OBMJQRLIQQTJLR-FRTGXRTISA-N

SMILES: O=C1C=2C=CC=C(OC)C2C(=O)C=3C(O)=C4C(=C(O)C13)CC(O)(C(=NNC(=O)CCCCCN5C(=O)C=CC5=O)CO)CC4OC6OC(C)C(O)C(N)C6

Sinonimi:

• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, (1-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-hydroxyethylidene)hydrazide, (2S-cis)-
• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, 2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, [1-[4-[(3-amino-2,3,6-trideoxy-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide, (2S-cis)-
• 2,5-Dihydro-2,5-dioxo-1H-pyrrole-1-hexanoic acid (1-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-hydroxyethylidene)hydrazide, (2S-cis)-
• Aldoxorubicin
• Doxo-Emch
• Doxorubicin-EMCH
• MC-Doxhzn
• N'-[(1E)-1-{4-[(3-amino-2,3,6-trideoxyhexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl}-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide
• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, 2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, [1-[4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide, (2S-cis)-
• Doxorubicin(6-maleimidocaproyl)hydrazone

1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, 2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide

CAS: 151038-96-9

• Formula: C₃₇H₄₂N₄O₁₃
• Peso molecolare: 750.7484

Doxorubicin-hydrazone-caproyl-maleimide

CAS: 151038-96-9

• Formula: C₃₇H₄₂N₄O₁₃
• Colore e forma: Neat
• Peso molecolare: 750.75

Doxorubicin-hydrazone-caproyl-maleimide

CAS: 151038-96-9

a 6-maleimidocaproyl hydrazone derivative of Doxorubicin which is an albumin binding prodrug. It is acid …

• Formula: C₃₇H₄₂N₄O₁₃
• Purezza: Min. 95%
• Colore e forma: Powder
• Peso molecolare: 750.75 g/mol

MC-DOXHZN

CAS: 151038-96-9

Mc-doxhzn is a protein-binding prodrug of DOXUbicin (DNA topoisomerase II inhibitor) with acid sensitivity.

• Formula: C₃₇H₄₂N₄O₁₃
• Purezza: 98%
• Colore e forma: Solid
• Peso molecolare: 750.75